Lab to Lives
Download on the App Store

Lab to Lives episodes

  • Creating virtuous cycles in drug development with Rob Freishtat

    Send us Fan Mail

    Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.

    • Current market uncertainty and investment challenges in biotech, especially for rare disease research
    • Approximately two-thirds of clinical trial processes add no value and aren't required by regulations
    • Many clinical trial failures occur not because drugs don't work but because trials can't recruit enough patients
    • Companies often treat development phases as "islands" rather than planning for commercial success from the beginning
    • Rare disease economics require greater efficiency since development costs must be recovered from much smaller patient populations
    • Reviving shelved drug candidates represents a potentially valuable opportunity
    • Patients should have greater input in trial design and outcome measures that matter to them
    • Better communication between sponsors and regulators could significantly improve drug development


    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    46 min
  • Bridging Academia and Biotech: Creating Innovators of Tomorrow with Jonathon Hill

    Send us Fan Mail

    Jonathan Hill takes us on a fascinating journey through the cutting-edge world of DNA sequencing and its revolutionary potential for early disease detection. As both an academic professor at Brigham Young University and co-founder of Wasatch BioLabs, Hill shares how third-generation sequencing technologies are transforming our ability to identify diseases years before symptoms appear.

    The conversation centers on a groundbreaking approach using native methylation calling—a method that identifies specific chemical modifications to DNA—to detect neurodegeneration in conditions like Alzheimer's and Parkinson's. Hill explains how these diseases damage the brain for up to a decade before symptoms emerge, creating a critical window where treatment could be most effective. By detecting the unique methylation signatures of dying neurons from cell-free DNA in the bloodstream, Wasatch BioLabs' technology aims to revolutionize diagnosis and treatment monitoring.

    What makes this platform particularly powerful is its versatility. The same technology that identifies dying neurons can be adapted to detect signatures from other dying cell types, potentially offering early diagnostics for autoimmune diseases, various cancers, and other conditions—all from a simple blood draw.

    Beyond the science, Hill reveals his passion for nurturing the next generation of biotech entrepreneurs. He's created a unique ecosystem at BYU where students with innovative ideas receive the mentorship, lab facilities, and business connections needed to translate academic discoveries into real-world applications. Drawing parallels to the tech boom of Silicon Valley, Hill emphasizes that biotech is experiencing its moment of explosive innovation, though with unique regulatory and infrastructure challenges.

    The episode concludes with a thoughtful discussion on regulatory hurdles in life sciences and how streamlining these processes—while maintaining safety standards—could accelerate innovation and save countless lives. For anyone fascinated by the intersection of cutting-edge science, entrepreneurship, and healthcare transformation, this conversation offers an inspiring glimpse into the future of medicine.

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    33 min
  • From Lab to Patient: Why Vector Design Makes or Breaks Cell Therapies with Alan Griffith

    Send us Fan Mail

    Vectors are the unsung heroes of cell and gene therapy—molecular couriers that transport therapeutic genes into human cells to treat disease. But as Alan Griffith, Head of Global Operations at Vector Builder reveals, creating these sophisticated delivery vehicles is far more complex than most realize.

    Drawing from over a decade of experience developing gene therapies before joining the CDMO sector, Griffith offers rare insight into what makes manufacturing these therapies so challenging. Vector design emerges as the critical yet underappreciated factor determining success or failure. "The fundamental sequence and vector composition itself is so fundamental to manufacturability," Griffith explains, noting how seemingly minor elements can dramatically impact production at scale. This knowledge has evolved painfully over the past decade, with clinical holds and manufacturing failures teaching hard lessons.

    The relationship between therapy developers and contract manufacturers proves equally crucial. Rather than transactional exchanges, successful partnerships require deep collaboration and shared risk. "Working with a CDMO is like dancing with someone you don't know," Griffith observes, emphasizing how Vector Builder aims to understand diseases and vector compositions thoroughly rather than simply executing manufacturing orders.

    Cost remains perhaps the greatest challenge facing cell and gene therapies. While small molecule drugs might be considered expensive at $10,000 per dose, that figure would be remarkably affordable for gene therapies. Strategies to address this include better vector design to reduce manufacturing failures, more targeted delivery requiring smaller doses, and challenging the "one-and-done" assumption that has proven more complex in reality as expression often diminishes over time.

    Looking ahead, Griffith sees complementary roles for both viral vectors and emerging non-viral delivery systems like lipid nanoparticles and exosomes. He predicts viral vectors will continue to dominate certain applications for decades due to their unmatched effectiveness, while non-viral approaches may offer manufacturing advantages and potentially lower costs.

    Cell and gene therapies are revolutionary treatments with vectors serving as "molecular couriers" that deliver genetic materials to target cells, but manufacturing these therapies presents significant challenges in scaling, cost, and regulatory compliance.

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    57 min
  • Tomorrow's Cures Are Hiding in Today's Patient Records with Vish Srivastava

    Send us Fan Mail

    The untapped potential of electronic health records has long been recognized in clinical research, but extracting meaningful insights from this treasure trove of data has remained an elusive challenge—until now.

    Vish Srivastava, founder of Century Health, reveals how artificial intelligence is revolutionizing real-world evidence by unlocking critical patient data trapped in EHRs. Traditional patient registries that once took a decade to amass just 1,000 patients can now be created with unprecedented efficiency through AI-powered data extraction. The breakthrough lies in advanced language models that can interpret unstructured clinical notes, transforming them into structured, analyzable data points while maintaining patient privacy.

    This technological revolution has profound implications across the drug development lifecycle. In multiple sclerosis research, analyzing 10+ years of longitudinal patient data has illuminated disease progression patterns beyond relapses, informing the next generation of treatments. For approved medications like GLP-1s, real-world evidence is uncovering potential applications in conditions ranging from metabolic disorders to neurodegenerative diseases, potentially fast-tracking label expansions that would traditionally require years of additional clinical trials.

    The vision is transformative: reducing the $2.6 billion, 12-year journey of drug development to a fraction of that time while ensuring treatments reach the right patients faster. While Century Health initially focuses on gastroenterology, neurology, and rheumatology in the US market, the underlying technology promises to revolutionize clinical research globally. As Vish notes, "It feels like we can create dramatically better outcomes for patients if we can just make the data that's already collected from their care accessible and actionable."

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    25 min
  • Championing Diversity to Transform Clinical Research with Shelli Pavone

    Send us Fan Mail

    Join us for a conversation with guest Shelli Pavone, co-founder of Inlightened, to uncover the untapped potential of diversity in clinical trials. Discover how historical mistrust, structural barriers, and exclusion criteria continue to hinder diverse patient recruitment. Shelli sheds light on the transformative impact inclusive trials have on scientific integrity, safety, and the generalizability of results. By embracing diversity, not only do we align with regulatory expectations, but we also pave the way for innovation and trust in our healthcare systems. This episode promises to expand your understanding of why diversity in trial participation is a scientific necessity rather than just a moral obligation.

    Explore the importance of diversifying clinical trial staff to boost trial success and enrollment rates. Shelli discusses breaking the mold of traditional investigator homogeneity by incorporating minority physicians, which fosters trust and enhances trial outcomes. Her insights into the creation of Inlightened reveal a passion for revolutionizing access to healthcare expertise, championing diverse voices, and pushing for equitable innovation. Uncover how Enlightened endeavors to challenge the constraints of conventional investment patterns and encourages the industry to embrace ideas that promise greater societal benefits. 

    This episode covers: 

    • Exploration of historical mistrust in clinical trials
    • Challenges faced in diversifying patient recruitment
    • Benefits of having diverse voices in clinical research
    • The FDA's evolving stance on diversity in clinical trials
    • The role of diverse investigators in influencing patient enrolment
    • Strategies to reduce barriers and increase participation
    • Shelli's journey and passion for healthcare innovation
    • The overarching need for change in the clinical trial landscape

    Shelli Pavone: https://www.linkedin.com/in/shelli-pavone-a729b2/ 

    Inlightened: https://getinlightened.com/ 

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    33 min
  • Revolutionizing Neurological Care: Andreas Forsland and Gregg Johns on Assistive Technology and Brain-Computer Interfaces

    Send us Fan Mail

    In this episode we dive into Brain-Computer Interface (BCI) technology, where the brain's faint signals are harnessed to create life-changing applications. Andreas Forsland and Greg Johns emphasize the importance of community-driven innovation, guided by the Brainiac Council—a unique assembly of patients, caregivers, and experts. This collaborative approach ensures that the solutions developed address real-world challenges, improving communication and independence for those with severe impairments. The discussion also highlights a groundbreaking clinical trial with the University of Waterloo, showcasing how AI-enhanced devices can reduce social isolation and enhance quality of life.

    We also cover:

    • Importance of user feedback in product design 
    • Communication technology for ALS, Parkinson's, and more 
    • The regulatory challenges of medical device development 
    • Integrating AI to improve user experience and interaction 
    • Future vision for accessible health technology 
    • Ethical considerations surrounding brain-computer interfaces

    Guests:
    Andreas Forsland: https://www.linkedin.com/in/andreasforsland/
    Gregg Johns: https://www.linkedin.com/in/gregg-johns-product-leader/ 

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    57 min
  • Revolutionizing Patient Recruitment in Clinical Trials: Unlocking Access and Accelerating Drug Development with Jill Pellegrino

    Send us Fan Mail

    This episode reveals alarming statistics about patient access to clinical trials, highlighting that only 3% of patients currently have access to participate. Our guest, Jill Pellegrino, CEO of Auto Recruitment, shares innovative strategies to engage the other 90% of the patient population and discusses the importance of digital advertising, pre-screening, and patient support in the recruitment process.

    • Discussion on the low percentage of patient access to clinical trials 
    • Barriers for physicians and research sites in patient enrollment 
    • Strategies to engage patients through digital advertising 
    • Importance of pre-screening for trial eligibility 
    • The role of EMR technology in improving recruitment 
    • Ensuring patient engagement post-initial interest 
    • Feedback and response from clinical trial sites 
    • Future plans for wider patient access to clinical trials 
    • Emphasis on patient-centric approaches in clinical research 

    This week, if you have any questions about Auto Recruitment or want to connect with Jill, visit https://www.autorecruitment.com.

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    30 min
  • Navigating the Shift: From SAS to R in Clinical Trials with Sunil Gupta

    Send us Fan Mail

    Why has SAS been the cornerstone of clinical trials for decades, and what is causing the shift to R now? Join us on "Transformation in Trials" as we explore this pivotal transition with Sunil Gupta, a seasoned programmer who has navigated both worlds. Sunil elaborates on SAS's long-standing dominance due to its robust programming capabilities and ease of use for FDA reviewers. However, the landscape is changing as R garners attention for its graphical prowess and collaborative potential. The conversation highlights the growing trend of new graduates versed in R and Python, which alleviates the shortage of SAS programmers and signifies a modernization wave in clinical trials, ultimately aiming to accelerate drug development.

    Our discussion takes a deep dive into the collaborative spirit driving this transition, particularly through initiatives like Pharmaverse. This specialized extension of Tidyverse is designed to optimize clinical data workflows within the pharmaceutical industry. Sunil shares insights into how clinical programming is evolving, focusing on standardized data models and the unification of CDISC standards. The conversation underscores the importance of collaboration and resource sharing, allowing organizations to tackle complex challenges efficiently and improve patient outcomes while adapting to R's open-source environment and its growing acceptance in pharmaceutical submissions.

    Transitioning from SAS to R is not just about adopting a new tool; it's about mastering new skills and embracing change. Sunil discusses the challenges he faced when learning R, from understanding its functional approach to navigating intricate syntax. He offers personal anecdotes that reflect his journey and the broader industry shift, emphasizing the importance of validation processes and resource optimization. As we conclude this episode, we express gratitude for the platform to discuss these transformative changes and invite listeners to engage with us on future topics, continuing to share success stories that inspire more organizations to embrace the power of R.

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    35 min
  • Enhancing Vendor Oversight and Communication Strategies in Clinical Trials with Jessica Cordes

    Send us Fan Mail

    Prepare to transform your understanding of vendor oversight in clinical trials as we welcome Jessica Cordes, a senior consultant and trainer at the Clinical Excellence Consultancy. Jessica brings her wealth of experience to highlight the intricate responsibilities that sponsors must navigate when outsourcing tasks. Our conversation promises to equip you with insights on maintaining control, mitigating risks, and leveraging technology like AI and machine learning to future-proof your oversight strategies.

    Metrics are more than numbers—they're a lifeline in managing vendor relationships. Learn how robust oversight can impact patient safety and compliance metrics. We’ll explore the necessity of tailoring KPIs to specific risks and the importance of a risk-based approach that starts from vendor selection and continues through ongoing management. Jessica’s emphasis on creating a standard operating procedure framework will guide you in ensuring consistency and accountability in sponsor-vendor interactions.

    Effective communication is the cornerstone of successful clinical trials. Through personal anecdotes and practical advice, we tackle the challenges of unit-based contracts and introduce milestone-based contracts for enhanced efficiency. From vendor selection to team building, Jessica shares her consultancy insights tailored for small and mid-sized biotech and pharma companies. We also consider the upcoming ICH E6 R3 guidance, emphasizing fit-for-purpose procedures in quality management systems, all while advocating for improved collaboration among stakeholders to enhance patient-centricity and accelerate drug development.

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    48 min
  • Navigating Cell and Gene Therapy: Insights and Challenges with Dr. Bruce Levine

    Send us Fan Mail

    How do you navigate the complexities of manufacturing cell and gene therapies that are tailored to individual patients? Find out as we sit down with Dr. Bruce Levine from the University of Pennsylvania to unpack the intricacies of clinical research in this groundbreaking field. From the unique emphasis on chemistry, manufacturing, and controls (CMC) to the logistical hurdles of sourcing and modifying patient-derived cells, Dr. Levine offers an expert's perspective on the challenges and advancements that set these therapies apart from traditional drugs. We also shine a light on the vital role of the International Society for Cell and Gene Therapy in driving forward these innovative treatments.

    In another riveting segment, we delve into the recent FDA investigation into cases of T-cell malignancies following CAR T-cell therapy. With data gleaned from voluntary reporting databases, we scrutinize causality, immortal time bias, and the need for improved reporting standards. Dr. Levine shares his thoughts on the importance of thorough patient follow-up and effective communication of risks and benefits. We also explore the evolution of cell and gene therapy, tracing Dr. Levine's journey from his early days in immunology research to his pivotal role in shaping the field. This episode is a must-listen for anyone interested in the dynamic and ever-evolving world of cell and gene therapy.

    Support the show


    ________
    Reach out to Ivanna Rosendal or send us a video or audio message

    Join the conversation on our LinkedIn page

    Visit www.labtolives.com 


    Hosts

    Alexander Booth

    Chiara Chianese

    Ivanna Rosendal Oshida 

    35 min

About Lab to Lives

From the publisher's feed

A simple question started this show: How do we medicine from the lab to making a difference in people's lives as quickly as possible? 


The answers are complex. Actual…